Virtual Reality and Neuropsychiatric Rehabilitation in Patients With Global Developmental Delay.

Sponsor
IRCCS Centro Neurolesi "Bonino-Pulejo" (Other)
Overall Status
Recruiting
CT.gov ID
NCT05879952
Collaborator
(none)
100
1
2
58
1.7

Study Details

Study Description

Brief Summary

Global Developmental Delay is a disorder characterized by failure achievement of expected milestones in different areas of psychomotor development before 5 years of age. Recent data in the literature have emphasized the importance of early therapeutic intervention. However, few specific interventions have been described in the literature for this disorder.

Among the high-tech tools used in recent years for rehabilitation, the BTs Nirvana is one of the semi-immersive system that can also be used in children, which allows to stimulate cognitive and motor domains. Objective of this single-blind, randomized, controlled study is to evaluate the feasibility and the effectiveness of integrated rehabilitation treatments with the use of BTs Nirvana in patient with Global Developmental Delay.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: TAU + BTsN session
  • Behavioral: TAU
N/A

Detailed Description

Global Developmental Delay (GDD) is a disorder characterized by failure achievement of expected milestones in different areas of psychomotor development before 5 years of age. The estimated incidence of GDD is 1-3% (Vasudevan et al., 2017), an early diagnosis and an efficacy treatment could provide a better long-term prognosis. Recent literature data have underlined the importance of early diagnosis followed by appropriate therapeutic management. In fact, GDDs could evolve into different neurodevelopmental disorders, especially if associated with other risk factors, such as intrauterine growth retardation, nutrient deficiencies, breastfeeding and maternal education, scarce social and economic conditions, poor learning opportunities, inadequate quality of caregiver-child interactions (Srour et al., 2006).

In recent decades, the use of virtual reality (VR) for therapeutic reason has become more and more popular for innovative treatments in cognitive-motor domain. Indeed, VR and the interactive playing can motivate children to learn new skills (Harris & Reid, 2005). Among the high-tech tools used in recent years for rehabilitation, the BTs Nirvana (BTsN) is one of the semi-immersive VR that can also be used in children, which allows to stimulate cognitive and motor domains (De Luca et al., 2021). The aim of this single-blind, randomized, controlled study is to evaluate the feasibility and the effectiveness of integrated rehabilitation treatments with the use of BTsN in patient with Global Developmental Delay.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Virtual Reality and Neuropsychiatric Rehabilitation: a Single-blind, Randomized, Controlled Pilot Study in Patients With Global Developmental Delay.
Actual Study Start Date :
Dec 1, 2020
Anticipated Primary Completion Date :
Sep 30, 2025
Anticipated Study Completion Date :
Sep 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental Group (EG)

The group consists of 50 patients diagnosed with global developmental delay, randomply assigned. The patients underwent treatment as usual (TAU) integrated with the use of BTsN pediatric modules, in a 1:1 ratio. All the exercises have been customized by the therapists according to the individual treatment needs, adapting the level of difficulty to the patient's abilities. Overall, each patient was treated over a period of 6 months, up to a total of n. 48 sessions, twice a week, lasting 45 minutes each.

Behavioral: TAU + BTsN session
BTsN treatment session included exercises aimed at identifying, finding, chasing or moving objects, with the aim of improving the perceptual-cognitive skills of each patient, through audio-visual stimuli and feedback implementing visuo-spatial skills and spatial cognition, allowing at the same time motor coordination and balance improvement.
Other Names:
  • standard neuro-psychomotor training + virtual reality game sessions
  • Active Comparator: Control Group (CG)

    The group consists of 50 patients diagnosed with global developmental delay randomply assigned. The patients underwent TAU, consisting in standard neuro-psychomotor training. The treatment was tailored according to each child's goals need and preferences. Overall, each patient was treated over a period of 6 months, up to a total of n. 48 sessions, twice a week, lasting 45 minutes each.

    Behavioral: TAU
    neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
    Other Names:
  • neuro-psychomotor training
  • Outcome Measures

    Primary Outcome Measures

    1. Griffiths-III Mental Development Scale (GMDS-III) [T0 (Baseline) - T1 (6 Months)]

      Assessment tool for children from 0 to 72 months and was for performed to assess Global Quotient (GQ)

    2. Clinical Global Impressions (CGI) [T0 (Baseline) - T1 (6 Months)]

      Scale that allows to quantify and monitor patients' progress and response to treatment over time, providing a judgment on global improvement.

    3. Protocol adherence [T0 (Baseline) - T1 (6 Months)]

      The number of non-delivered treatment sessions will be counted, and the percentage of deviation will be calculated compared to the total number of treatment sessions.

    Secondary Outcome Measures

    1. The Child Behavior Checklist (CBCL 1½-5) [T0 (Baseline) - T1 (6 Months)]

      This questionnarie is a caregiver report to identifying problem behavior in children.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    12 Months to 66 Months
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients diagnosed with diagnosis of GDD, according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria;

    • age between 12 and 66 months;

    • patients without significant medical conditions such as epilepsy, significant visual and auditory sensory deficits, traumatic brain injury, or other significant genetic disorders.

    • Signed informed consent and the availability of at least one family member to participate in the diagnostic/therapeutic process.

    Exclusion Criteria:
    • children not aged between 12 and 66 months;

    • significant medical conditions such as epilepsy, significant visual and auditory sensory deficits, traumatic brain injury, or significant genetic disorders.

    • Informed consent not signed of at least one family member to participate in the diagnostic/therapeutic process.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 IRCCS Neurolesi Bonino Pulejo Messina Italy 98124

    Sponsors and Collaborators

    • IRCCS Centro Neurolesi "Bonino-Pulejo"

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Francesca Cucinotta, Principal Investigator, IRCCS Centro Neurolesi "Bonino-Pulejo"
    ClinicalTrials.gov Identifier:
    NCT05879952
    Other Study ID Numbers:
    • Nir01
    First Posted:
    May 30, 2023
    Last Update Posted:
    May 30, 2023
    Last Verified:
    May 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of May 30, 2023